Page 1 of 1

Consolidation therapy following chemoimmunotherapy in B-cell chronic lymphocytic leukaemia: infection-related deaths reported with the use of MabCampath

Bayer HealthCare and Genzyme, in collaboration with Health Canada, informed of important safety information regarding the use of MabCampath ( Alemtuzumab ) as consolidation therapy following combination treatment with other chemotherapeutic or biologic agents. MabCampath is a recombinant humanize...
Read Article

Six infection-related deaths reported after treatment with MabCampath in patients with B-cell chronic lymphocytic leukemia

Bayer Schering Pharma AG and Genzyme Europe BV have informed Healthcare Professionals on six infection-related deaths, reported from a trial ( CALGB10101 ) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia patients were treated with Fludarabine ( Fludara ) and Rituximab...
Read Article

Multiple sclerosis: Campath more effective than Rebif

Two-year interim results from a Phase 2 trial comparing Campath ( Alemtuzumab ) with Rebif ( Interferon beta-1a ) for the treatment of multiple sclerosis have demonstrated statistically significant efficacy of Campath compared to Rebif. The phase 2 trial randomized 334 patients with active relaps...
Read Article

Chronic lymphocytic leucemia, MRD-negative remission with Alemtuzumab improves survival

The 84 percent of patients who had no detectable traces of chronic lymphocytic leukemia ( CLL ) after receiving Alemtuzumab had survived for at least 5 years. A study, led by Peter Hillmen from the Leeds General Infirmary, Leeds ( UK ), evaluated whether eradication of minimal residual disease ( ...
Read Article